文献速递糖尿病

房水视黄醇结合蛋白3浓度降低与糖尿病黄斑水肿及糖尿病视网膜病变进展相关

Reduced Aqueous Retinol-Binding Protein 3 Concentration Is Associated With Diabetic Macular Edema and Progression of Diabetic Retinopathy.
PubMed 文献 · Diabetes Care · 2025-01-01

在乔斯林糖尿病中心接受白内障手术的153只眼(149例患者)中,房水RBP3中位数从无DR眼的2.1 nmol/L降至轻中度NPDR眼的1.5 nmol/L(P=0.047)。基线RBP3升高与无DME病史相关(β=-0.701,95%CI -1.151至0.250,P=0.002),平均随访5.5±3.6年,与后续DR进展较少相关(OR 0.51,95%CI 0.28-0.93,P=0.03)。

要点

  • 房水RBP3在无DR眼为2.1 nmol/L,轻中度NPDR眼为1.5 nmol/L(P=0.047)。
  • 基线RBP3升高与无DME病史相关(β=-0.701,95%CI -1.151至0.250,P=0.002)。
  • 基线RBP3升高与后续DR进展较少相关(OR 0.51,95%CI 0.28-0.93,P=0.03)。

核心结论

  • 本研究提示房水RBP3可能是重要的保护因素,是DME或DR进展的首个神经视网膜特异性生物标志物,并可能是潜在治疗靶点。

研究设计与样本

  • 在乔斯林糖尿病中心接受白内障手术的患者中,用ELISA法测定房水RBP3浓度。
  • 共153只眼(31只眼为1型糖尿病,122只眼为2型糖尿病;n=149例患者)。
  • DR进展定义为早期治疗糖尿病视网膜病变研究严重程度量表上两步或以上恶化,DME病史由临床诊断确定。

主要发现

  • 37%的眼无DR体征,40%为轻度非增殖性DR(NPDR),23%为中度NPDR。
  • 房水RBP3从无DR眼的中位数2.1 nmol/L(四分位距0.8-3.4)降至轻中度NPDR眼的1.5 nmol/L(0.8-3.8)(P=0.047)。
  • 1型与2型糖尿病患者的房水RBP3水平差异无显著差异。
  • RBP3升高与无DME病史相关(β=-0.701,95%CI -1.151至0.250,P=0.002)。
  • 平均随访5.5±3.6年,基线RBP3升高与后续DR进展较少相关(OR 0.51,95%CI 0.28-0.93,P=0.03)。

关键数值与推荐

  • 多变量分析中,RBP3仍与DR进展和DME病史显著相关。
  • 将RBP3加入预测DR进展的临床模型后,曲线下面积改善5%(P<0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the association of aqueous retinol-binding protein 3 (RBP3) with history of diabetic macular edema (DME) and diabetic retinopathy (DR) progression. RESEARCH DESIGN AND METHODS: RBP3 concentration was measured by ELISA in aqueous from patients undergoing cataract surgery at Joslin Diabetes Center. DR progression was defined as two-step or more worsening on the Early Treatment Diabetic Retinopathy Study severity scale, and DME history was determined by clinical diagnosis. RESULTS: In 153 eyes (31 with type 1 and 122 with type 2 diabetes; n = 149 patients), 37% had no signs of DR, 40% had mild nonproliferative DR (NPDR), and 23% had moderate NPDR. Aqueous RBP3 decreased from a median of 2.1 nmol/L (interquartile range 0.8-3.4) in eyes with no DR to 1.5 nmol/L (0.8-3.8) in eyes with mild-to-moderate NPDR (P = 0.047). The difference between aqueous RBP3 levels in those with type 1 or type 2 diabetes was not significant. Elevated RBP3 (β = -0.701, 95% CI -1.151 to 0.250, P = 0.002) was associated with no DME history. With a mean follow-up of 5.5 ± 3.6 years, elevated RBP3 at baseline was associated with less subsequent DR progression (odds ratio 0.51, 95% CI 0.28-0.93, P = 0.03). In multivariable analyses, RBP3 remained significantly associated with a DR progression and history of DME. A 5% improvement was seen in the area under the curve when RBP3 was added to clinical models for predicting DR progression (P < 0.05). CONCLUSIONS: This study suggests that aqueous RBP3 may be an important protective factor, the first neuroretinal-specific biomarker of DME or DR progression, and a possible therapeutic target.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Chokshi T, Fickweiler W, Jangolla S, et al. Reduced Aqueous Retinol-Binding Protein 3 Concentration Is Associated With Diabetic Macular Edema and Progression of Diabetic Retinopathy. Diabetes Care. 2025. PMID: 39566017. doi:10.2337/dc24-1260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。